CD8A and neoplasm: The formulation provided protection to the enzyme and targeting capacity to the antibody, resulting in an enhanced anti-PD-1 tumor accumulation and a reduced tumor hypoxia with an increased number of CD8 + T cells; additionally, there was a reduced tumor growth and an increased survival time in vivo [24].